Published :
Tables : 50
Figures : 44
Category : Healthcare
No. of Pages : 231
Report Code : HC-U4437
Europe Prostate Cancer Drugs Market Overview: FutureWise Market Research has instantiated a report that provides an intricate analysis of Europe Prostate Cancer Drugs Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Europe Prostate Cancer Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Europe Prostate Cancer Drugs Market: • GlaxoSmithKline • AstraZeneca plc • Johnson & Johnson • Sanofi S.A • Bayer AG • Novartis • Elekta • Theragenics • Pfizer Inc. • Abbot Laboratories • Genentech • Roche • AbbVie • Varian Medical Systems (Note: The list of the major players will be updated with the latest market scenario and trends) Europe Prostate Cancer Drugs Market Segmentation: By Type • Hormone Sensitive Prostate Cancer • Hormone Refractory Prostate Cancer By Therapy • Hormonal Therapy • Chemotherapy • Immunotherapy • Targeted Therapy By End User • Hospitals • Clinics • Others By Region • Germany • U.K • France • Italy • Spain • Russia • Poland • Rest of Europe Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Europe Prostate Cancer Drugs Market By Type, By Therapy, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— Germany, U.K, France, Italy, Spain, Russia, Poland, Rest of Europe • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customisation offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of Europe Prostate Cancer Drugs Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Europe Prostate Cancer Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Europe Prostate Cancer Drugs Market: • GlaxoSmithKline • AstraZeneca plc • Johnson & Johnson • Sanofi S.A • Bayer AG • Novartis • Elekta • Theragenics • Pfizer Inc. • Abbot Laboratories • Genentech • Roche • AbbVie • Varian Medical Systems (Note: The list of the major players will be updated with the latest market scenario and trends) Europe Prostate Cancer Drugs Market Segmentation: By Type • Hormone Sensitive Prostate Cancer • Hormone Refractory Prostate Cancer By Therapy • Hormonal Therapy • Chemotherapy • Immunotherapy • Targeted Therapy By End User • Hospitals • Clinics • Others By Region • Germany • U.K • France • Italy • Spain • Russia • Poland • Rest of Europe Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Europe Prostate Cancer Drugs Market By Type, By Therapy, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— Germany, U.K, France, Italy, Spain, Russia, Poland, Rest of Europe • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customisation offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Europe Prostate Cancer Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Product Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Europe Prostate Cancer Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Product Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Product Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Europe Prostate Cancer Drugs Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Hormone Sensitive Prostate Cancer 7.2. Hormone Refractory Prostate Cancer 8. Europe Prostate Cancer Drugs Market, By Therapy Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Hormonal Therapy 8.2. Chemotherapy 8.3. Immunotherapy 8.4. Targeted Therapy 9. Europe Prostate Cancer Drugs Market, by End User Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Hospitals 9.2. Clinics 9.3. Others 10. Europe Prostate Cancer Drugs Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 10.2.1. Germany 10.2.2. U.K 10.2.3. France 10.2.4. Italy 10.2.5. Spain 10.2.6. Russia 10.2.7. Poland 10.2.8. Rest of Europe 10.3. Market Size (USD Million) Forecast for Europe 2020-2027 11. Market Share Analysis and Competitive Landscape 11.1. Europe Landscape - Key Players, Revenue and Presence 11.2. Europe Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 11.3. Europe Emerging Companies 11.4. Europe - Market Share Analysis and Key Regional Player 11.5. Europe Key Player - Growth Matrix 12. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 12.1. GlaxoSmithKline 12.1.1. Company Overview 12.1.2. Product Portfolio 12.1.3. SWOT Analysis 12.1.4. Financial Overview 12.1.5. Strategic Overview 12.2. AstraZeneca plc 12.2.1. Company Overview 12.2.2. Product Portfolio 12.2.3. SWOT Analysis 12.2.4. Financial Overview 12.2.5. Strategic Overview 12.3. Johnson & Johnson 12.3.1. Company Overview 12.3.2. Product Portfolio 12.3.3. SWOT Analysis 12.3.4. Financial Overview 12.3.5. Strategic Overview 12.4. Sanofi S.A 12.4.1. Company Overview 12.4.2. Product Portfolio 12.4.3. SWOT Analysis 12.4.4. Financial Overview 12.4.5. Strategic Overview 12.5. Bayer AG 12.5.1. Company Overview 12.5.2. Product Portfolio 12.5.3. SWOT Analysis 12.5.4. Financial Overview 12.5.5. Strategic Overview 12.6. Novartis 12.6.1. Company Overview 12.6.2. Product Portfolio 12.6.3. SWOT Analysis 12.6.4. Financial Overview 12.6.5. Strategic Overview 12.7. Elekta 12.7.1. Company Overview 12.7.2. Product Portfolio 12.7.3. SWOT Analysis 12.7.4. Financial Overview 12.7.5. Strategic Overview 12.8. Theragenics 12.8.1. Company Overview 12.8.2. Product Portfolio 12.8.3. SWOT Analysis 12.8.4. Financial Overview 12.8.5. Strategic Overview 12.9. Pfizer Inc. 12.9.1. Company Overview 12.9.2. Product Portfolio 12.9.3. SWOT Analysis 12.9.4. Financial Overview 12.9.5. Strategic Overview 12.10. Abbot Laboratories 12.10.1. Company Overview 12.10.2. Product Portfolio 12.10.3. SWOT Analysis 12.10.4. Financial Overview 12.10.5. Strategic Overview 12.11. Genentech 12.11.1. Company Overview 12.11.2. Product Portfolio 12.11.3. SWOT Analysis 12.11.4. Financial Overview 12.11.5. Strategic Overview 12.12. Roche 12.12.1. Company Overview 12.12.2. Product Portfolio 12.12.3. SWOT Analysis 12.12.4. Financial Overview 12.12.5. Strategic Overview 12.13. AbbVie 12.13.1. Company Overview 12.13.2. Product Portfolio 12.13.3. SWOT Analysis 12.13.4. Financial Overview 12.13.5. Strategic Overview 12.14. Varian Medical Systems 12.14.1. Company Overview 12.14.2. Product Portfolio 12.14.3. SWOT Analysis 12.14.4. Financial Overview 12.14.5. Strategic Overview 13. Pre and Post COVID-19 Impact 13.1. Positive influence on the healthcare industry 13.2. The financial disruption of the manufacturing sector 13.3. Impact of COVID-19 on emerging companies 13.4. Significant mandates in the healthcare regulations initiated by administrations 13.5. The overall economic slowdown of the developing and developed nations 14. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics